1	The distribution of antimicrobial resistance genes across phylogroup, host species and
2	geography in 16,000 publicly-available <i>E. coli</i> genomes
3	
4	Elizabeth Pursey <sup>1,2*</sup> , Tatiana Dimitriu <sup>1</sup> , William H. Gaze <sup>3</sup> , Edze R. Westra <sup>1</sup> and Stineke van
5	Houte <sup>1</sup>
6	
7	<sup>1</sup> Environment and Sustainability Institute, Biosciences, University of Exeter, Penryn,
8	Cornwall, United Kingdom
9	<sup>2</sup> Department of Experimental Medicine, University of Lund, Sweden
10	<sup>3</sup> European Centre for Environment and Human Health, University of Exeter Medical School,
11	University of Exeter, Penryn, Cornwall, United Kingdom
12	
13	*Correspondence to: ellie.pursey@gmail.com
14	Key words: antimicrobial resistance, E. coli, phylogroups, hosts, regions
15	
16	Abstract
17	
18	E. coli is a highly diverse bacterial species that generates a huge global burden of
19	antimicrobial-resistant infections. A wealth of whole genome sequence data is available on
20	public databases for this species, presenting new opportunities to analyse the distribution of
21	antimicrobial resistance (AMR) genes across its genetic and ecological diversity. We
22	extracted and categorised metadata on host species and geographic location and combined
23	this with <i>in silico</i> phylogrouping to describe the characteristics of ~16,000 assembled <i>E. coli</i>
24	genomes from the NCBI RefSeq database. We estimated AMR carriage using various
25	metrics: counts of overall genes, multidrug- and extensively drug-resistant categories, and
26	selected $\beta$ -lactamases of current global concern - $bla_{CTX-M}$ and carbapenemase genes. We
27	present estimates of AMR carriage for these metrics by species type (human,
28	agricultural/domestic animal, wild birds and other wild animals), geographic subregion, and
29	across phylogroups. In addition, we describe the distribution of phylogroups within host types
30	and geographic subregions. Our findings show high AMR carriage in commensal-associated
31	phylogroups, agricultural and wild animal hosts and in many subregions. However, we also
32	quantify large biases in sequencing data, the substantial gaps in our knowledge of AMR in
33	many hosts, regions and environmental settings, and the need for systematic sampling to gain
34	a more accurate picture.

## 35 Introduction

36

37 *Escherichia coli* is a remarkably diverse species both genetically and ecologically. It occupies 38 various niches, ranging from a commensal of many warm-blooded organisms, to a globally 39 devastating pathogen, to a free-living environmental bacterium [1]. It is a leading cause of 40 mortality associated with drug-resistant infections and was the pathogen responsible for the 41 most deaths attributed to antimicrobial resistance (AMR) in 2019 [2]. In addition, 42 carbapenem-resistant and extended-spectrum  $\beta$ -lactamase (ESBL)-producing E. coli are 43 World Health Organization priority pathogens, for which development of new antibiotics is 44 urgently needed [3]. In light of the ongoing AMR crisis, it is necessary to understand how 45 resistance genes are distributed across the ecological and genetic diversity of this species, 46 highlighting the potential risks they pose across contexts. 47 48 AMR genes (ARGs) are part of the substantial accessory gene content found in E. coli [4], 49 and therefore are not distributed uniformly across the species phylogeny. Acquired ARGs are 50 particularly important due to their extensive ability to transmit horizontally in populations on 51 mobile elements such as plasmids, leading to AMR spread across more distant locations and 52 genetic lineages [5]. Some of these ARGs present significant clinical risks in humans, 53 particularly those with current or potential spread across bacterial host genetic backgrounds. 54 including to other species, and along the commensal-pathogen continuum [6]. 55 56 Most research has focused on AMR in human-associated and pathogenic isolates [7]. A study 57 focusing on ~1,000 isolates selected to represent the diversity of *E. coli*, mostly including 58 isolates from non-clinical origins, found ARGs were associated with strains from humans and 59 domesticated animals, independent of phylogroup [8]. Therapeutic and growth promoter 60 usage of antibiotics in agriculture is well-documented, and has been linked to high rates of 61 AMR in livestock-associated isolates [9]. Resistance may also spill over into wild animal 62 populations, and there is increasing evidence of wildlife as potential reservoirs of AMR [10]. 63 A One Health approach to AMR emphasises the interconnectedness of human, animal and 64 environmental microbiomes [11], with the potential for bidirectional flow of ARGs between 65 animal (wild or domesticated), crop, natural and built environment, and human microbiomes. 66 There are also geographic and socioeconomic biases in studies of AMR in E. coli. Whilst 67 antibiotics are used most in high-resource settings, the burden of AMR is estimated to

disproportionately affect lower and middle income countries, despite the scarcity of data inthese regions [2].

70

71 A wealth of previous work on E. coli has investigated AMR trends in specific settings, such 72 as individual hospitals or farms. As sequencing technologies become more accessible and 73 public genomic databases grow, much larger genomics-based studies of AMR in highly-74 sampled species like *E. coli* are becoming increasingly feasible. For example, a recent large-75 scale study of over 70,000 E. coli genomes found that the number of distinct ARGs varied 76 between phylogroups, and that specific resistance genes were found more frequently in some, 77 though the pattern of resistance to antibiotic classes remained stable across groups [12]. 78 Another study curated a collection of ~10,000 E. coli isolates sampled from human sources, 79 and identified lineages where >50% of isolates were MDR [13]. 80 81 In this work we expand on previous large-scale genomic studies of ARGs in *E. coli* by 82 investigating diversity across different host categories and geographic subregions, as well as 83 phylogroups. We characterise a final dataset of ~16,000 publicly-available assembled E. coli 84 genomes, documenting the distribution of ARGs according to several metrics: counts of 85 ARGs, multidrug- and extensively drug-resistant (MDR and XDR) classifications, and 86 presence of clinically-important  $\beta$ -lactamases (*bla*<sub>CTX-M</sub> and carbapenemases). First, we used 87 model comparison to assess the contributions of host, subregion and phylogroup towards 88 explaining ARG variation in E. coli. Then, we used generalised linear models (GLMs) to 89 describe the probabilities of MDR, *bla*<sub>CTX-M</sub> and carbapenemase presence according to the 90 same predictors. To do so, we used subsampling and resampling approaches to correct for 91 sample size disparities between groupings, and investigate the sensitivity of trends according 92 to subsample sizes. 93 94 Methods 95 96 Genomes 97 98 The initial complete dataset of 26,881 E. coli genomes was retrieved from the National 99 Center for Biotechnology Information (NCBI) RefSeq database in February 2022 in 100 nucleotide fasta format using ncbi-genome-download v0.3.0 (https://github.com/kblin/ncbi-

101 genome-download).

1	02
т	04

## 103 Detection of ARGs, phylogrouping and retrieval of metadata

104

105 NCBI AMRFinderPlus v3.10.21 was used to predict the identity of acquired ARGs [14]. 106 Clermont phylogrouping [15] was performed *in silico* using the EzClermont command-line 107 tool [16]. Snakemake v6.2.1 [17] was used to generate a pipeline for phylogrouping and 108 detecting ARGs, which was run using the University of Exeter's Advanced Research 109 Computing facilities. We removed efflux (*acrF*, *emrD* and *mdtM*) and *blaEC*  $\beta$ -lactamase 110 genes from the dataset, as they were either very common or ubiquitous. As we could not use 111 phenotypic resistance categories, we used the classes included in NCBI AMRFinderPlus 112 output as a proxy for categorising genomes as multidrug-resistant (MDR; ARGs conferring 113 resistance to  $\geq 3/20$  antibiotic classes) and extensively drug-resistant (XDR; ARGs conferring 114 resistance to  $\geq 10/20$  antibiotic classes) [18]. 115 116 Host and location metadata were retrieved and categorised using the Bio.Entrez utilities from 117 Biopython v1.77. We filtered genomes for those with complete metadata for host species and 118 geographic location, as well as those not typed as *E. coli* by phylogrouping, which excluded 119 10,609 genomes, resulting in a final dataset of 16,272 genomes. Geographic locations were 120 split into 20 subregions (Fig. S1) according to Natural Earth data 121 (https://www.naturalearthdata.com/). 122 123 All genomes were sorted into the following host species categories: 'Human', 124 'Agricultural/Domestic animals', 'Wild birds' and 'Wild animals'. This was achieved using 125 regular expressions constructed by manually reviewing text in the 'host' field of the 126 biosample data for each accession number. Wild birds were separated from other wild 127 animals due to their comparatively large numbers of genomes, high mobility and potential for 128 ARG spread [19]. Any animal that is most likely to be associated with humans, such as 129 'mouse' or 'canine', was assigned to the 'Agricultural/Domestic animals' category, which 130 also included farm animals such as cows and chickens. Broader responses that could not be 131 reliably classified into any specific group, such as 'Animal', and 'Avian', were not included 132 in further analyses, as well as animals likely to be human food sources such as mussels. 133 Though a conservative approach was taken when assigning genomes to wild animal or bird 134 host groups, these classifications determine the likely category of the host based on species, 135 and cannot rule out cases such as zoo animals.

136	
137	Statistical analysis
138	
139	Data tidying and statistical analysis was done using R v4.0.4, with dplyr v1.0.1, ggplot2
140	v3.3.6 [20] and MetBrewer [21] for colour palettes. Maps additionally used the R packages sf
141	1.0-7 [22] and rnaturalearth v0.1.0.
142	
143	In all cases, binomial GLMs were fitted using glmmTMB v1.1.5 [23]. To assess model fit,
144	simulated residuals were plotted and their dispersion tested using DHARMa v0.4.5 [24].
145	Prior to all statistical modelling, subgroupings with sample sizes $\leq 100$ (e.g. Central Asia)
146	were removed from the dataset. Sample sizes for each predictor in the full dataset are shown
147	in Figure 1A-C.
148	
149	Initially, maximal models were fitted using the entire dataset with MDR, XDR or bla <sub>CTX-M</sub>
150	genes as a binomial response variable (presence/absence) and all explanatory variables
151	included (host, phylogroup and subregion). For carbapenemase genes, the same response
152	variables were used, but only host and phylogroup were included as predictors due to lack of
153	data coverage for many subregions for these comparatively rare genes. Sample sizes for all
154	combinations of response variable and predictor are shown in Tables S1-3. Next, Akaike
155	information criterion (AIC) scores were used to assess the fit of all possible models using the
156	<i>dredge</i> function from MuMIn v1.46.0. In all cases, large $\triangle$ AIC values (>50) were seen
157	between the maximal model and the next best model (Table S4), emphasising the
158	contribution of all variables to the distribution of AMR gene measures. Model coefficients for
159	all maximal models are shown in Table S5.
160	
161	Next, subsampling approaches were used to circumvent disparities in sampling sizes between
162	groups. Separate models were made for each predictor due to the difficulty in 1) taking single
163	representative subsamples spanning all hosts, phylogroups and subregions and 2) estimating
164	means from models with multiple categorical explanatory variables. A subsample was taken
165	for each predictor, giving datasets with equal numbers of genomes from each phylogroup,
166	host or subregion. Several subsample sizes were used to determine the sensitivity of trends to
167	the sample size. Firstly, the dataset was subsampled without replacement down to the lowest
168	group size for each model (e.g. all host categories were sampled to n=234, the sample size for

169 wild birds). In addition, samples with replacement were taken with increasing sizes (n=500,

170 1000, 2000 and 4000) for hosts, phylogroups and subregions, to investigate the robustness of
171 trends to changing sample sizes. All single predictor models were also run with the full, non172 subsampled dataset.

173

174 Model estimated means and 95% confidence intervals (CIs) were calculated using ggpredict 175 from the ggeffects package [25]. Model coefficients are presented in Table S6 for host, Table 176 S7 for subregion and Table S8 for phylogroup. We did not perform post-hoc comparisons or 177 report *P*-values in the manuscript due to the large number of pairwise comparisons that would 178 be necessary (e.g. 91 comparisons for each model of subregion data). In addition, we did not 179 have *a priori* hypotheses about group differences to test, but rather aimed to describe the 180 patterns in the data with our modelling approaches. Finally, many groups had large sample 181 sizes, which can produce a significant result even for a biologically insignificant effect size 182 [26, 27]. 183 184 **Results** 185 186 Quantification of sample sizes across hosts, phylogroups and subregions in the RefSeq 187 dataset 188 189 Initially, we characterised the RefSeq dataset by looking at sample sizes across phylogroups, 190 host categories, and geographic subregions (Fig. 1A-C, Tables S1-3). Phylogroups B1, A and 191 B2 collectively made up 74% (12,109/16,272) of genomes, with smaller numbers found 192 across C, E, F, G and U (Fig. 1A). Sixty-five genomes were typed as U/cryptic or cryptic. 193 The majority of genomes had a sampling location in North America (n=5,202) or Eastern 194 Asia (n=3,790), whilst many regions were represented poorly such as Micronesia, Melanesia 195 and Polynesia (n=1 for all), Central Asia and Caribbean (n=3 for both) and Middle Africa 196 (n=10) (Fig. 1B). Finally, 96% of the *E. coli* genomes were isolated from humans and 197 agricultural or domestic animals (15,549/16,272) with only 234 from wild birds and 489 from 198 other wild animals (Fig. 1C). 199



201 Figure 1 – Total number of genomes per A) phylogroup, B) geographic subregion and C) host species

202 category. Counts of ARGs for D) phylogroup, E) geographic subregion and F) host species category,

203 with raw data plotted below boxplots. G) Proportion of genomes in each phylogroup per host

- 204 category.
- 205

206 ARG counts across the diversity of E. coli sequences

207

208 We measured counts of ARGs detected across the diversity of genomes to get an overall 209 measure of how AMR carriage was distributed across the dataset (Fig. 1D-F). Overall, the 210 mean number of ARGs per genome for the entire dataset was 5.75. Median ARG counts were 211 highest in phylogroups C, F and A (9, 8 and 7 respectively; Fig. 1D). Meanwhile the lowest 212 median counts were in groups E (0) and B1 (1). A wide range of ARG counts was also seen 213 between and within subregions (Fig. 1E). Among the most well-sampled regions, genomes 214 from Eastern Asia had the highest median ARG count (8), though relatively high numbers 215 were also seen in Western Europe (median ARG count = 5). Additionally, higher median 216 ARG numbers were seen in less represented regions such as Northern (8.5), Middle (9) and 217 Southern Africa (6) and Central Asia (9). High within-group diversity in ARG counts was 218 again seen for host categories, with highest median counts in genomes from humans (5) and 219 agricultural animals (3).

220

221 Hosts and subregions show different phylogroup patterns

222

223 We investigated the distribution of *E. coli* phylogroups within hosts (Fig. 1G) and geographic

subregions (Fig. S2). E. coli isolates from agricultural and domestic animals mostly belonged

to phylogroups A and B1 (n=1,863 and n=2,354, respectively). Those from humans were

226 most likely to belong to phylogroup B2 (n=2,870), as well as A and B1 (n=2,071 and

227 n=2,000 respectively). There were also comparatively high numbers of phylogroup D isolates

in genomes from human hosts (n=1,237). A higher proportion of phylogroup F isolates were

seen in wild birds (n=54), whilst wild animals had slightly higher proportions of B2 isolates

230 (n=74) than agricultural or domesticated animals.

231

232 The frequencies of different phylogroups varied between geographic subregions (Fig. S2).

233 While A, B1 and B2 were typically the largest groups, their relative proportions varied. For

example, B1 was more common in Eastern (n=195) and Western (n=94) Africa, B2 was

- highest in Australia and New Zealand (n=216) and Eastern Europe (n=112), while A was
- most common in South-Eastern (n=131) and Western (n=117) Asia. Isolates belonging to
- 237 phylogroup D were also relatively common, with notably higher proportions in regions
- 238 including Northern Africa (n=17) and Eastern Europe (n=86).
- 239
- 240 Specific measures of AMR carriage
- 241
- Following characterisation of the dataset, we began analysing more specific measures of
- 243 AMR carriage. First, we categorised genomes as MDR ( $\geq$  1 ARGs conferring resistance to  $\geq$
- 244 3 classes) and XDR ( $\geq$  1 ARGs conferring resistance to  $\geq$  10 classes) following detection of
- 402 unique resistance genes conferring predicted resistance to 19 classes. We also looked at
- 246 the presence of selected  $\beta$ -lactamase genes of current global health concern. We detected 40
- unique  $bla_{\text{CTX-M}}$  genes across the final dataset, most commonly  $bla_{\text{CTX-M-15}}$  (n=2,536),  $bla_{\text{CTX-M}}$
- 248  $M_{-14}$  (n=1,063) and *bla*<sub>CTX-M-55</sub> (n=903). Meanwhile, a total of 46 different carbapenemases
- 249 from the NDM, KPC, OXA, IMP, VIM, IMI and GES classes were identified, the most
- 250 frequent being NDM-5 (n=893), KPC-2 (n=264), NDM-1 (n=219) and OXA-48 (n=189).
- 251
- We generated model estimated mean proportions with 95% CIs for models of MDR (Fig. 2), XDR (Fig. S3) and *bla*<sub>CTX-M</sub> (Fig. 3) presence, according to host, phylogroup and subregion for both the full dataset, and a dataset subsampled down to the smallest group size without replacement to adjust for large sample size differences between groups. The same process was repeated for carbapenemase gene presence (Fig. 4), but subregion was not used as a predictor due the rarity of carbapenemase-positive genomes across many regions. Trends were broadly consistent across the two datasets and estimates for the full dataset are quoted in
- the subsequent text.
- 260
- *1. MDR and XDR 261*
- 262

263 MDR genomes were common, with a given genome from the majority of phylogroups,

subregions and hosts having > 0.4 probability of being MDR (Fig. 2). Within phylogroups,

265 multidrug resistance was most common in groups C (0.83, 95% CI=0.80-0.86), F (0.75, 95%

- 266 CI=0.71-0.78) and A (0.72, 95% CI=0.70-0.73), whilst being comparatively uncommon in
- 267 group E isolates (0.25, 95% CI=0.22-0.28). Isolates from humans (0.60, 95% CI=0.58-0.60)
- and agricultural/domestic hosts (0.51, 95% CI=0.50-0.52) had the highest probabilities of

- 269 MDR, though estimates from wild animals (0.44, 95% CI=0.39-0.48) and birds (0.43, 95%
- 270 CI = 0.37-0.50) were reasonably high. Finally, South-Eastern Asia (0.86, 95% CI = 0.83-0.90)
- and Western Africa (0.78, 95% CI=0.15-0.72) had the highest estimated proportions of MDR
- genomes, while the lowest were in Northern America (0.40, 95% CI=0.38-0.41) and Central
- 273 America (0.42, 95% CI=0.33-0.52).
- 274
- 275 XDR genomes were less common, and not detected at high enough frequencies to estimate
- their probabilities in the minimum subsampled dataset for phylogroup B2 and wild animal
- hosts (Fig. S3). The phylogroups with the highest probabilities of XDR were A (0.092, 95%
- 278 CI=0.083-0.10) and F (0.07, 95% CI=0.052-0.093), whilst remaining very low for B2 (0.003,
- 279 95% CI=0.0018-0.0058) and E (0.018, 95% CI=0.012-0.03). The highest XDR probabilities
- 280 were estimated in wild birds (0.13, 95% CI=0.091-0.18), with probabilities below 0.06 for
- 281 other host categories. Finally, XDR genomes were by far the most likely to occur in Eastern
- 282 Asia (0.16, 95% CI=0.14-0.17), and below 0.08 for all other regions.
- 283





Figure 2 –Estimated mean probabilities and 95% CIs of MDR from binomial GLMs for datasets
subsampled without replacement to the minimum group size for A) phylogroup, B) host category and
C) geographic subregion. The same model types for the full non-subsampled dataset for D)
phylogroup, E) host category and F) geographic subregion. CIs for subregion models can be found in
Figure S6.

290

## 291 2. bla<sub>CTX-M</sub> and carbapenemase genes

- 292
- 293 The presence of the  $bla_{\text{CTX-M}}$  class of  $\beta$ -lactamases was highly variable between groups (Fig.
- 294 3). Estimated probabilities ranged from 0.08 (95% CI = 0.066-0.11) in phylogroup E to 0.51
- 295 (95% CI=0.47-0.55) in phylogroup F, whilst *bla*<sub>CTX-M</sub> genes were more associated with
- human hosts (0.33, 95% CI=0.32-0.34) than other host categories. The probabilities of

297 *bla*<sub>CTX-M</sub> genes being present also varied widely between subregions, with the highest in

298 South-Eastern Asia (0.59, 95% CI=0.53-0.64) and Eastern Europe (0.52, 95% CI=0.47-0.57),



and all other subregions below 0.45.

300

Figure 3 – Estimated mean probabilities and 95% CIs of *bla*<sub>CTX-M</sub> presence from binomial GLMs for
datasets subsampled without replacement to the minimum group size for A) phylogroup, B) host
category and C) geographic subregion. The same model types for the full non-subsampled dataset for
D) phylogroup, E) host category and F) geographic subregion. CIs for subregion models can be found
in Figure S12.

306

307 Carbapenamase genes were far less common than  $bla_{CTX-M}$  genes (Fig. 4). There was a clear 308 split between phylogroups C, F, A and D, which were more likely to possess carbapenemases 309 (probabilities >0.15), and the remaining groups which had probabilities of 0.05 or below. The

310 highest proportions of carbapenemases were estimated in wild bird (0.25, 95% CI=0.20-0.31)

311 and human (0.14, 95% CI= 0.13-0.15) hosts.

312

313 We further investigated sampling bias for carbapenemase-positive isolates in wild birds due

to the high proportion of genomes possessing these genes. Isolates from wild birds possessing

315 carbapenemases were only represented in 3 subregions: Australia and New Zealand (n=25),

- Eastern Asia (n=32) and Western Asia (n=1). Sequencing bias was evident; for example, 68
- 317 out of 234 wild bird isolates were from one study of silver gulls in Australia (which made up
- 318 68 out of the 93 isolates from this region). This study (PRJNA630096) specifically sought
- 319 and sequenced isolates conferring resistance to critically important antimicrobials. Further
- 320 carbapenemase-producing isolates came from studies in China (PRJNA669620 and
- 321 PRJNA349231) that specifically studied carbapenem-resistant *E. coli*.
- 322



Figure 4 – Estimated mean probabilities and 95% CIs of carbapenemase presence from binomial
GLMs for datasets subsampled without replacement to the minimum group size for A) phylogroup
and B) host category. The same model types for the full non-subsampled dataset for C) phylogroup
and D) host category.

328



330	
331	Due to the large discrepancies in sample size between hosts, regions and phylogroups in this
332	dataset, we used additional sampling with replacement to examine the sensitivity of the
333	observed trends to changing sample sizes of 500, 1000, 2000 and 4000 (Fig. S4-S12). This
334	showed that, although fluctuations in estimated proportions occurred (as well as expected
335	reductions in CIs with increased sample size), broader trends were reproducible across wide
336	variations in subsample size. In some smaller subsamples, insufficient genomes possessed the
337	metric of AMR carriage (e.g. a carbapenemase gene) to make estimates in some
338	subgroupings.
339	
340	Discussion
341	
342	Though we are in the era of large-scale genomics studies, with thousands of genomes
343	available for species such as E. coli, it remains challenging to collate this information to
344	answer questions about AMR prevalence. In this study, we characterised the RefSeq E. coli
345	dataset for which metadata was available, investigating sampling bias and AMR carriage
346	according to various metrics for different hosts, phylogroups and geographic subregions.
347	
348	How evenly sampled are publicly-available E. coli genomes?
349	
350	In first characterising this dataset, large sample size discrepancies in the locations and hosts
351	E. coli genomes were sourced from were apparent. This was not unexpected. Previous large-
352	scale work on E. coli genomes isolated from human hosts has emphasised the sampling
353	biases towards clinically-important isolates and lineages, as well as high-income countries,
354	even in the most well-sampled host species [13]. Other work has used literature searches to
355	quantify how poorly sampled wild animals are for E. coli, with small within-group sample
356	sizes in the few studies available [28]. Our data adds to this body of knowledge emphasising
357	how little is known about ARG burden across the diversity of this species, despite the vast
358	amount of sequencing data available.
359	
360	We investigated the effects of subsampling all groups to the minimum sample size, as well as
361	resampling up to larger sample sizes. This approach cannot replace unbiased sampling,
362	particularly for those groups that are less well represented. However, it is interesting to note

363 that estimates of AMR carriage for larger groups, such as phylogroup A or human hosts, did

not alter substantially regardless of the subsampling regime. Additionally, the spread of

365 counts of ARGs was wide in these groups, indicating that they were not necessarily

- dominated by one or few lineages.
- 367

368 Previous work has also investigated the potential effect of sampling bias on AMR estimates 369 using *E. coli* genomes from GenBank [29]. These authors found that 1) the average distance 370 of a given newly sequenced *E. coli* genome is equivalent to that between known close 371 relatives, such as O157:H7 genomes, and 2) the results of a population genetics analysis of 372 AMR did not change substantially when all human or unknown source genomes were 373 removed, or all genomes for which the GenBank record referenced antibiotic resistance. 374 Therefore, it is possible that, for more well-sampled subgroupings of E. coli, our current 375 sequence collection already spans a high diversity of this species. 376

377 Phylogroup distributions within hosts and subregions

378

Though the most common phylogroups were A, B1 and B2, their proportions varied

380 substantially between hosts. Phylogroup B1 was the most frequent in agricultural and wild

animals. This is broadly consistent with many smaller-scale studies for which B1 was the

382 most frequent in agricultural settings. For example, B1 made up 71% of agriculture-

associated isolates in a study in the Philippines [30], 50% of those in a study of sheep farming

in China [31], and 35% of isolates from cattle and their attendants in Tanzania [32]. The wide

385 variation in actual proportions observed in these different studies may be due to smaller

sample sizes (n=17-100 in those referenced), as well as location and species effects. Human

387 isolates were proportionally more likely to be B2 than those from other hosts. E. coli isolates

from group B2 tend to possess more virulence traits than those from A and B1, though this

virulence is proposed to be a by-product of commensalism [33]. Geographic differences in

390 predominant commensal *E. coli* phylogroups have broadly represented a shift from A to B2

in industrialised nations over the past decades, with these being the most common

392 phylogroups in humans [34]. We saw this trend to some extent – European regions and

393 Australia and New Zealand had high proportions of B2. Contrastingly, we found that other

regions such as North America and Eastern Asia had B1 as the predominant phylogroup.

395

396 Estimating AMR carriage across phylogroups, hosts and subregions

398 We used various metrics of AMR carriage to get an overview of ARG distribution in 399 publicly-available *E. coli* genomes. When comparing phylogroups, A, C and F were 400 repeatedly associated with more ARGs as well as clinically-important  $\beta$ -lactamases. 401 Phylogroup A is a major group that appears to be more generalist. It is spread across 402 vertebrate hosts [8], and contains mostly human commensal strains [35] as well as laboratory 403 strains [36]. Although the presence of engineered strains may partly explain the high AMR 404 metrics in this group, our results also imply that ARGs may be frequent in commensal 405 lineages. Phylogroups commonly present in the human gut could be a reservoir for resistance 406 genes and plasmids [37], potentially allowing their horizontal spread into other, more 407 problematic lineages or species.

408

409 As they are minor phylogroups, comparatively less is known about groups C and F. In terms 410 of pathogenic potential, the sequence type complex 88 (STc88) lineage of group C is one of 411 the main avian pathogenic E. coli (APEC) strains [38]. This phylogroup also includes ST410, 412 a recently-emerged MDR lineage with fluoroquinolone resistance, ESBL (*bla*<sub>CTX-M-15</sub>) and 413 carbapenemase ( $bla_{OXA-181}$  and  $bla_{NDM-5}$ ) genes [38]. Meanwhile, phylogroup F has been 414 associated with fewer virulence traits than closely related groups [39], though it has also been 415 linked to extraintestinal pathogenic (ExPEC) infections [38] and contains the MDR STc648 416 lineage [40]. Therefore, these phylogroups could represent highly virulent and/or drug-417 resistant lineages and may warrant further investigation.

418

419 Unsurprisingly, human hosts were associated with more ARGs than other host categories. 420 However, high levels were also seen in agricultural and domestic animal species for some 421 measures, such as MDR. In addition, *bla*<sub>CTX-M</sub> and carbapenemase genes were detected in all 422 the animal host categories to some degree. Antibiotics are still extensively used in animal 423 agriculture, selecting for ARGs both directly in the gut and through excretion of antibiotics 424 into soil and the local environment [41]. Despite this there is no standardised global 425 surveillance system used in animal agriculture that is equivalent to those used in humans 426 [41]. There is evidence for transmission of *bla*<sub>CTX-M</sub> variants in *E. coli* from humans to farmed 427 animals and the environment, which also occurs in the reverse direction via food products 428 [42]. Only limited studies document the occurrence of carbapenemases in E. coli strains from 429 wildlife, agricultural animals and soils, though they have been reported in these contexts [43, 430 44]. This highlights the need for further prevalence studies to determine the extent to which 431 these genes are spreading in different environments.

432

The proportionally high numbers of carbapenemase-possessing isolates (and potentially XDR
isolates) from wild birds in this work are likely due to studies that enriched for ARGs.
However, this emphasizes our lack of knowledge on the true extent of AMR spread in the
natural world. High levels of problematic ARGs in wild birds, particularly generalist species,
could occur due to their relatively high mobility compared to other taxa, and their utilisation
of diverse foraging habitats, both of which increase potential exposure to anthropogenic
sources of resistant bacteria [45, 46].

440

441 Finally, estimates of ARG prevalence varied geographically depending on the metric used. 442 The highest AMR carriage was generally estimated for Eastern and South-Eastern Asia 443 across measures. However, other regions were particularly high for individual measures. For 444 example, Eastern Europe had high levels of  $bla_{CTX-M}$  genes and MDR genomes were more 445 common in Western Africa. These trends could either reflect genuine differences in AMR 446 levels and individual gene prevalence, or regional differences in sampling strategies and 447 genomic surveillance. There are large gaps in AMR surveillance for low and middle income 448 (LMIC) countries. A recent study utilised the relationship between socioeconomic 449 characteristics and AMR prevalence to model AMR levels for underrepresented countries, 450 estimating high levels of third-generation cephalosporin resistance in *E. coli* from Western 451 Asia [47]. Genomic surveillance has been leveraged during the COVID-19 pandemic and for 452 other infectious diseases, but next-generation sequencing capacity is low in many regions 453 [48]. However, the development of more many sequence analysis tools to detect ARGs [49], 454 as well as developing capacity to incorporate whole genome sequencing into AMR 455 surveillance in LMICs [50], may lead to this becoming a powerful tool in the future. 456

457 Public genomic databases – limitations, benefits and future work

458

We show the void in sequencing data from *E. coli* isolates outside of human and agricultural settings in a very large dataset, as well as stark regional disparities, with scarce publiclyavailable data representing the majority of global regions. Whilst this study characterises this currently available dataset, representative estimates of ARG burden in *E. coli* sequences cannot be made without systematic, representative sampling. Notably, it is concerning that ARGs that inactivate our last-resort antibiotics are being detected and potentially spread in any environmental context, and that we do not have sufficient genomic data to investigate

466	this. Despite their limitations, publicly-available datasets are important, allowing access to
467	sequencing data for scientists and the public across the globe, as well as improving
468	reproducibility. Future systematic sampling and genomic surveillance in previously under-
469	investigated settings will give a more accurate picture of the scale of the AMR problem.
470	
471	Data Summary
472	
473	All code used to generate and analyse data are available at
474	https://github.com/elliekpursey/AMR-Ecoli.
475	
476	Author contributions
477	
478	EP, SVH and ERW conceptualised the study. WHG refined the directions of the analysis and
479	methodology. EP performed all data and statistical analysis and wrote the first manuscript
480	draft. All authors contributed to interpretation of the results and editing subsequent versions
481	of the manuscript.
482	
483	Conflicts of interest
484	
485	We declare no conflicts of interest.
486	
487	Acknowledgements and funding
488	
489	EP was supported by a PhD studentship equally funded by a grant from the European
490	Research Council under the European Union's Horizon 2020 research and innovation
491	programme (ERC-STG-2016-714478 to ERW) and the College of Life and Environmental
492	Sciences, University of Exeter, UK. EP thanks Liam Langley for statistical modelling advice,
493	and Elze Hesse and Kate Baker for feedback on the analyses. TD is supported by European
494	Research Council (ERC-2017-ADG-788405 to ERW). SVH acknowledges BBSRC for
495	funding (BB/R010781/1 and BB/S017674/1).
496	
497	References
498	

- Luo C, Walk ST, Gordon DM, Feldgarden M, Tiedje JM, *et al.* Genome sequencing of
   environmental Escherichia coli expands understanding of the ecology and speciation of
   the model bacterial species. *Proc Natl Acad Sci* 2011;108:7200–7205.
- 502 2. Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Aguilar GR, *et al.* Global burden of
   503 bacterial antimicrobial resistance in 2019: a systematic analysis. *The Lancet* 504 2022;399:629–655.
- 3. World Health Organization. Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis. 9789240026438 (electronic version); Geneva: World Health Organization; 2017.
- 4. Hall RJ, Whelan FJ, Cummins EA, Connor C, McNally A, *et al.* Gene-gene
  relationships in an Escherichia coli accessory genome are linked to function and mobility. *Microb Genomics* 2021;7:000650.
- 5. Von Wintersdorff CJH, Penders J, Van Niekerk JM, Mills ND, Majumder S, *et al.* Dissemination of antimicrobial resistance in microbial ecosystems through horizontal
   gene transfer. *Front Microbiol* 2016;7:1–10.
- 515 6. Zhang A-N, Gaston JM, Dai CL, Zhao S, Poyet M, *et al.* An omics-based framework
  516 for assessing the health risk of antimicrobial resistance genes. *Nat Commun*517 2021;12:4765.
- 518 7. Woolhouse M, Ward M, van Bunnik B, Farrar J. Antimicrobial resistance in humans,
  519 livestock and the wider environment. *Philos Trans R Soc B Biol Sci* 2015;370:20140083–
  520 20140083.
- 521 8. Touchon M, Perrin A, Sousa JAM de, Vangchhia B, Burn S, *et al.* Phylogenetic
  522 background and habitat drive the genetic diversification of Escherichia coli. *PLOS Genet*523 2020;16:e1008866.
- 524 9. Economou V, Gousia P. Agriculture and food animals as a source of antimicrobial 525 resistant bacteria. *Infect Drug Resist* 2015;8:49–61.
- Arnold KE, Williams NJ, Bennett M. 'Disperse abroad in the land': the role of wildlife
   in the dissemination of antimicrobial resistance. *Biol Lett* 2016;12:20160137.
- 11. Robinson TP, Bu DP, Carrique-Mas J, Fèvre EM, Gilbert M, et al. Antibiotic
   resistance is the quintessential One Health issue. *Trans R Soc Trop Med Hyg* 2016;110:377–380.
- 12. Petitjean M, Condamine B, Burdet C, Denamur E, Ruppé E. Phylum barrier and
   Escherichia coli intra-species phylogeny drive the acquisition of antibiotic-resistance
   genes. *Microb Genomics* 2021;7:000489.
- 13. Horesh G, Blackwell GA, Tonkin-Hill G, Corander J, Heinz E, et al. A
- comprehensive and high-quality collection of Escherichia coli genomes and their genes.
   *Microb Genomics* 2021;7:000499.

537 14. Feldgarden M, Brover V, Gonzalez-Escalona N, Frye JG, Haendiges J, et al. 538 AMRFinderPlus and the Reference Gene Catalog facilitate examination of the genomic 539 links among antimicrobial resistance, stress response, and virulence. Sci Rep 540 2021;11:12728. 541 15. Clermont O, Christenson JK, Denamur E, Gordon DM. The Clermont Escherichia 542 coli phylo-typing method revisited: improvement of specificity and detection of new 543 phylo-groups. Environ Microbiol Rep 2013;5:58-65. 544 16. Waters NR, Abram F, Brennan F, Holmes A, Pritchard L. Easy phylotyping of 545 Escherichia coli via the EzClermont web app and command-line tool. Access Microbiol. 546 17. Mölder F, Jablonski KP, Letcher B, Hall MB, Tomkins-Tinch CH, et al. Sustainable 547 data analysis with Snakemake. 10:33; F1000Research; 18 January 2021. 548 18. Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, et al. Multidrug-549 resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert 550 proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 551 2012;18:268-281. 552 19. Skarżyńska M, Zaja C M, Bomba A, Bocian Ł, Kozdruń W, et al. Antimicrobial 553 Resistance Glides in the Sky—Free-Living Birds as a Reservoir of Resistant Escherichia 554 coli With Zoonotic Potential. Front Microbiol;12. 555 https://www.frontiersin.org/articles/10.3389/fmicb.2021.656223 (2021, accessed 4 July 556 2022). 557 20. Wickham H, Averick M, Bryan J, Chang W, McGowan L, et al. Welcome to the 558 Tidyverse. J Open Source Softw 2019;4:1686. 559 21. Mills BR. MetBrewer: Color Palettes Inspired by Works at the Metropolitan Museum of 560 Art. 561 22. Pebesma E. Simple Features for R: Standardized Support for Spatial Vector Data. R J 562 2018;10:439. 563 23. Brooks M E, Kristensen K, Benthem K J, van, Magnusson A, Berg C W, et al. 564 glmmTMB Balances Speed and Flexibility Among Packages for Zero-inflated 565 Generalized Linear Mixed Modeling. R J 2017;9:378. 566 24. Hartig F. DHARMa: Residual Diagnostics for Hierarchical (Multi-Level / Mixed) 567 Regression Models. http://florianhartig.github.io/DHARMa/ (2020). 568 25. Lüdecke D. ggeffects: Tidy Data Frames of Marginal Effects from Regression Models. J 569 Open Source Softw 2018;3:772. 570 26. Sullivan GM, Feinn R. Using Effect Size—or Why the P Value Is Not Enough. J Grad 571 Med Educ 2012;4:279-282. 572 27. Berner D, Amrhein V. Why and how we should join the shift from significance testing 573 to estimation. J Evol Biol;n/a.

- 574 28. Lagerstrom KM, Hadly EA. The under-investigated wild side of Escherichia coli:
  575 genetic diversity, pathogenicity and antimicrobial resistance in wild animals. *Proc R Soc*576 *B Biol Sci* 2021;288:20210399.
- 577 29. Goldstone RJ, Smith DGE. A population genomics approach to exploiting the accessory
   578 'resistome' of Escherichia coli. *Microb Genomics* 2017;3:e000108.
- 30. Zara ES, Vital PG. Phylogroup typing and carbapenem resistance of Escherichia coli
  from agricultural samples in Metro Manila, Philippines. *J Environ Sci Health Part B*2022;57:644–656.
- 582 31. Zhao X, Lv Y, Adam FEA, Xie Q, Wang B, *et al.* Comparison of Antimicrobial
  583 Resistance, Virulence Genes, Phylogroups, and Biofilm Formation of Escherichia coli
  584 Isolated From Intensive Farming and Free-Range Sheep. *Front Microbiol*;12.
  585 https://www.frontiersin.org/articles/10.3389/fmicb.2021.699927 (2021, accessed 19 July
  586 2022).
- 32. Madoshi BP, Kudirkiene E, Mtambo MMA, Muhairwa AP, Lupindu AM, *et al.*Characterisation of Commensal Escherichia coli Isolated from Apparently Healthy Cattle
  and Their Attendants in Tanzania. *PLOS ONE* 2016;11:e0168160.
- 590 33. Le Gall T, Clermont O, Gouriou S, Picard B, Nassif X, *et al.* Extraintestinal Virulence
  591 Is a Coincidental By-Product of Commensalism in B2 Phylogenetic Group Escherichia
  592 coli Strains. *Mol Biol Evol* 2007;24:2373–2384.
- 593 34. Tenaillon O, Skurnik D, Picard B, Denamur E. The population genetics of commensal
   594 Escherichia coli. *Nat Rev Microbiol* 2010;8:207–217.
- 595 35. Smati M, Clermont O, Le Gal F, Schichmanoff O, Jauréguy F, *et al.* Real-Time PCR
  596 for Quantitative Analysis of Human Commensal Escherichia coli Populations Reveals a
  597 High Frequency of Subdominant Phylogroups. *Appl Environ Microbiol* 2013;79:5005–
  598 5012.
- 36. Abram K, Udaondo Z, Bleker C, Wanchai V, Wassenaar TM, et al. Mash-based
  analyses of Escherichia coli genomes reveal 14 distinct phylogroups. Commun Biol
  2021;4:1–12.
- 37. Hu Y, Yang X, Qin J, Lu N, Cheng G, *et al.* Metagenome-wide analysis of antibiotic
   resistance genes in a large cohort of human gut microbiota. *Nat Commun* 2013;4:2151.
- 38. Denamur E, Clermont O, Bonacorsi S, Gordon D. The population genetics of
  pathogenic Escherichia coli. *Nat Rev Microbiol*. Epub ahead of print 21 August 2020.
  DOI: 10.1038/s41579-020-0416-x.
- 39. Vangchhia B, Abraham S, Bell JM, Collignon P, Gibson JS, *et al.* Phylogenetic
   diversity, antimicrobial susceptibility and virulence characteristics of phylogroup F
   Escherichia coli in Australia. *Microbiology* 2016;162:1904–1912.
- 40. Johnson JR, Johnston BD, Gordon DM. Rapid and Specific Detection of the
  Escherichia coli Sequence Type 648 Complex within Phylogroup F. *J Clin Microbiol*2017;55:1116–1121.

- 41. Jadeja NB, Worrich A. From gut to mud: dissemination of antimicrobial resistance
  between animal and agricultural niches. *Environ Microbiol* 2022;24:3290–3306.
- 615 42. Bevan ER, Jones AM, Hawkey PM. Global epidemiology of CTX-M β-lactamases:
  616 temporal and geographical shifts in genotype. *J Antimicrob Chemother* 2017;72:2145–
  617 2155.
- 43. Furlan JPR, Sellera FP, Stehling EG. Strengthening genomic surveillance of
  carbapenemases in soils: a call for global attention. *Lancet Microbe*;0. Epub ahead of
  print 23 March 2023. DOI: 10.1016/S2666-5247(23)00093-9.
- 44. Köck R, Daniels-Haardt I, Becker K, Mellmann A, Friedrich AW, *et al.*Carbapenem-resistant Enterobacteriaceae in wildlife, food-producing, and companion animals: a systematic review. *Clin Microbiol Infect* 2018;24:1241–1250.
- 45. Navarro J, Grémillet D, Afán I, Miranda F, Bouten W, *et al.* Pathogen transmission
   risk by opportunistic gulls moving across human landscapes. *Sci Rep* 2019;9:10659.
- 46. Migura-Garcia L, Ramos R, Cerdà-Cuéllar M. Antimicrobial Resistance of *Salmonella* Serovars and *Campylobacter* spp. Isolated from an Opportunistic Gull
  Species, Yellow-legged Gull (*Larus michahellis*). J Wildl Dis 2017;53:148–152.
- 629 47. Oldenkamp R, Schultsz C, Mancini E, Cappuccio A. Filling the gaps in the global
  630 prevalence map of clinical antimicrobial resistance. *Proc Natl Acad Sci*631 2021;118:e2013515118.
- 48. Inzaule SC, Tessema SK, Kebede Y, Ogwell Ouma AE, Nkengasong JN. Genomic informed pathogen surveillance in Africa: opportunities and challenges. *Lancet Infect Dis* 2021;21:e281–e289.
- 635 49. Hendriksen RS, Bortolaia V, Tate H, Tyson GH, Aarestrup FM, et al. Using
- 636 Genomics to Track Global Antimicrobial Resistance. Front Public Health;7.
- 637
   https://www.frontiersin.org/articles/10.3389/fpubh.2019.00242 (2019, accessed 22 May

   638
   2023).
- 639 50. NIHR Global Health Research Unit on Genomic Surveillance of AMR. Whole-
- 640 genome sequencing as part of national and international surveillance programmes for 641 antimicrobial resistance: a roadmap. *BMJ Glob Health* 2020;5:e002244.
- 642